BioCentury
ARTICLE | Company News

Clinical Data, Merck KGaA deal

December 17, 2007 8:00 AM UTC

MRK received a milestone payment of 135,146 shares from CLDA under a 2004 deal under which CLDA received rights to develop and commercialize the antidepressant Vilazodone (see BioCentury, Sept. 27, 2...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article